Curated News
By: NewsRamp Editorial Staff
February 03, 2026

Oragenics Partners with DUCK FLATS Pharma to Advance Intranasal Concussion Therapy

Discuss on Substack
Original Source

TLDR

  • Oragenics partners with DUCK FLATS Pharma to accelerate FDA approval for ONP-002, gaining strategic advantage in developing the first intranasal concussion therapy.
  • Oragenics engages DUCK FLATS Pharma for FDA preparation and clinical trial design, aligning Australian Phase 2a trials with U.S. regulatory strategy for ONP-002.
  • This partnership advances a potential first-in-class concussion treatment, offering hope for improved neurological care and better outcomes for brain injury patients.
  • Oragenics' intranasal delivery platform could revolutionize treatment for concussion, Parkinson's, and Alzheimer's through innovative brain-targeted therapeutics.

Impact - Why it Matters

This development matters because concussions and mild traumatic brain injuries represent a significant public health concern affecting millions annually, from athletes to accident victims, with limited treatment options currently available. Oragenics' ONP-002, as a potential first-in-class intranasal therapy, could revolutionize concussion treatment by offering targeted brain delivery that may improve recovery outcomes and reduce long-term neurological complications. The partnership with DUCK FLATS Pharma accelerates the path toward FDA approval, potentially bringing this innovative treatment to patients sooner. Successful development could also validate Oragenics' intranasal platform for other neurological conditions like Parkinson's and Alzheimer's, addressing broader unmet medical needs in neurology.

Summary

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company, has announced a strategic partnership with DUCK FLATS Pharma to advance its innovative intranasal concussion therapy, ONP-002, toward U.S. development. This collaboration positions DUCK FLATS Pharma as Oragenics' U.S. Investigational New Drug readiness and regulatory execution partner, focusing on FDA-facing preparation and clinical trial design. The engagement is designed to align the company's upcoming Phase 2a clinical trial in Australia with its U.S. regulatory strategy, supporting progression toward a future U.S. Phase 2b trial and later-stage development. This move represents a significant step in Oragenics' mission to develop brain-targeted therapeutics through its proprietary intranasal delivery technology.

The company's lead candidate, ONP-002, is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury, addressing a critical unmet medical need in neurological care. Oragenics' intranasal delivery platform holds promise for multiple neurological conditions beyond concussion, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. The partnership with DUCK FLATS Pharma underscores Oragenics' commitment to rigorous regulatory preparation as it advances through clinical development stages. Investors and stakeholders can find more information through the company's newsroom at https://ibn.fm/OGEN, while the full press release is available at https://ibn.fm/1n4Ja, providing comprehensive details about this strategic development.

This announcement was distributed through BioMedWire (BMW), a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on biotechnology, biomedical sciences, and life sciences sectors. BioMedWire provides enhanced press release distribution, article syndication to 5,000+ outlets, and social media distribution via IBN to millions of followers, ensuring maximum visibility for Oragenics' strategic partnership announcement. The platform's comprehensive corporate communications solutions help companies like Oragenics reach investors, influencers, consumers, journalists, and the general public effectively. For more information about BioMedWire's services, visit https://www.BioMedWire.com, where breaking news and insightful content converge to provide actionable information about developments in the life sciences sector.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Partners with DUCK FLATS Pharma to Advance Intranasal Concussion Therapy

blockchain registration record for this content.